Clinical and laboratory profile of different dengue sub types in dengue virus infection

Background: Dengue infection, an arthropod-borne viral hemorrhagic fever is caused by Arbovirus of Flavivirus genus and transmitted by Aedes aegypti, Aedes albopictus. Liver involvement in dengue fever is manifested by the elevation of transaminases representing reactive hepatitis, due to direct attack of virus itself or the use of hepatotoxic drugs. The objective of the study was to investigate clinical and laboratory profile of different dengue sub type’s patients admitted for dengue fever.Methods: All the adult patients with clinical features such as fever and later confirmed positive by dengue serology test admitted as inpatients were included in the study. Vitals parameters and systemic examination were performed. Investigation of dengue serotology, liver function test, routine investigations like hemoglobin percentage, total count, ESR, packed cell volume, platelet count, partial thromboplastin and activated partial thromboplastin time, blood urea, serum creatinine, and blood sugar estimation were done.Results: On comparison of clinical signs in different dengue subgroups it was observed that the mean value of pulse, blood pressure and respiratory rate were significantly more deranged in the DSS group as compared to the DF group. Platelet count was significantly lower in all the sub groups whereas PT/aPTT was more dearranged in the DSS and DHF group as compared to the DF group. Comparison between the mean values of liver function test in different dengue sub groups had been shown, elevated transaminases, hypoproteinaemia and hypoalbuminaemia, in higher frequency in dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) as compared to classical dengue fever (DF) (P values significant). SGOT was significantly higher than the SGPT levels and SGOT was much more elevated in the DSS sub group compared to the DFS and DF group.Conclusions: The liver enzymes serum aminotransferase levels were significantly raised in patients with dengue shock syndrome compared to other two groups. Serum aminotransferases directly correlate with severity of infection in all the sub groups. Patients with secondary dengue infection were more prone for developing bleeding manifestations and shock syndrome.

Mutual visibility by luminous robots without collisions

We consider the Mutual Visibility problem for anonymous dimensionless robots with obstructed visibility moving in a plane: starting from distinct locations, the robots must reach, without colliding, a configuration where no three of them are collinear. We study this problem in the luminous robots model, in which each robot has a visible light that can assume colors from a fixed set. Among other results, we prove that Mutual Visibility can be solved in SSynch with 2 colors and in ASynch with 3 colors. If an adversary can interrupt and stop a robot moving to its computed destination, Mutual Visibility is still solvable in SSynch with 3 colors and, if the robots agree on the direction of one axis, also in ASynch. As a byproduct, we provide the first obstructed-visibility solutions to two classical problems for oblivious robots: collision-less convergence to a point (also known as near-gathering) and circle formation

Melter Throughput Enhancements for High-Iron HLW

This report describes work performed to develop and test new glass and feed formulations in order to increase glass melting rates in high waste loading glass formulations for HLW with high concentrations of iron. Testing was designed to identify glass and melter feed formulations that optimize waste loading and waste processing rate while meeting all processing and product quality requirements. The work included preparation and characterization of crucible melts to assess melt rate using a vertical gradient furnace system and to develop new formulations with enhanced melt rate. Testing evaluated the effects of waste loading on glass properties and the maximum waste loading that can be achieved. The results from crucible-scale testing supported subsequent DuraMelter 100 (DM100) tests designed to examine the effects of enhanced glass and feed formulations on waste processing rate and product quality. The DM100 was selected as the platform for these tests due to its extensive previous use in processing rate determination for various HLW streams and glass compositions

Final Report - Melt Rate Enhancement for High Aluminum HLW Glass Formulation, VSL-08R1360-1, Rev. 0, dated 12/19/08

The principal objective of the work reported here was to develop and identify HLW glass compositions that maximize waste processing rates for the aluminum limted waste composition specified by ORP while maintaining high waste loadings and acceptable glass properties. This was accomplished through a combination of crucible-scale tests, confirmation tests on the DM100 melter system, and demonstration at pilot scale (DM1200). The DM100-BL unit was selected for these tests since it was used previously with the HLW waste streams evaluated in this study, was used for tests on HLW glass compositions to support subsequent tests on the HLW Pilot Melter, conduct tests to determine the effect of various glass properties (viscosity and conductivity) and oxide concentrations on glass production rates with HLW feed streams, and to assess the volatility of cesium and technetium during the vitrification of an HLW AZ-102 composition. The same melter was selected for the present tests in order to maintain comparisons between the previously collected data. These tests provide information on melter processing characteristics and off-gas data, including formation of secondary phases and partitioning. Once DM100 tests were completed, one of the compositions was selected for further testing on the DM1200; the DM1200 system has been used for processing a variety of simulated Hanford waste streams. Tests on the larger melter provide processing data at one third of the scale of the actual WTP HLW melter and, therefore, provide a more accurate and reliable assessment of production rates and potential processing issues. The work focused on maximizing waste processing rates for high aluminum HLW compositions. In view of the diversity of forms of aluminum in the Hanford tanks, tests were also conducted on the DM100 to determine the effect of changes in the form of aluminum on feed properties and production rate. In addition, the work evaluated the effect on production rate of modest increases in melter operating temperature. Glass composition development was based on one of the HLW waste compositions specified by ORP that has a high concentration of aluminum. Small-scale tests were used to provide an initial screening of various glass formulations with respect to melt rates; more definitive screening was provided by the subsequent DM100 tests. Glass properties evaluated included: viscosity, electrical conductivity, crystallinity, gross glass phase separation and the 7- day Product Consistency Test (ASTM-1285). Glass property limits were based upon the reference properties for the WTP HLW melter. However, the WTP crystallinity limit (< 1 vol% at 950oC) was relaxed slightly as a waste loading constraint for the crucible melts

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Parkinson's Disease: Basic Pathomechanisms and a Clinical Overview

PD is a common and a debilitating degenerative movement disorder. The number of patients is increasing worldwide and as yet there is no cure for the disease. The majority of existing treatments target motor symptom control. Over the last two decades the impact of the genetic contribution to PD has been appreciated. Significant discoveries have been made, which have advanced our understanding of the pathophysiological and molecular basis of PD. In this chapter we outline current knowledge of the clinical aspects of PD and the basic mechanistic understanding

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

Clinical and laboratory profile of different dengue sub types in dengue virus infection

Background: Dengue infection, an arthropod-borne viral hemorrhagic fever is caused by Arbovirus of Flavivirus genus and transmitted by Aedes aegypti, Aedes albopictus. Liver involvement in dengue fever is manifested by the elevation of transaminases representing reactive hepatitis, due to direct attack of virus itself or the use of hepatotoxic drugs. The objective of the study was to investigate clinical and laboratory profile of different dengue sub type’s patients admitted for dengue fever.Methods: All the adult patients with clinical features such as fever and later confirmed positive by dengue serology test admitted as inpatients were included in the study. Vitals parameters and systemic examination were performed. Investigation of dengue serotology, liver function test, routine investigations like hemoglobin percentage, total count, ESR, packed cell volume, platelet count, partial thromboplastin and activated partial thromboplastin time, blood urea, serum creatinine, and blood sugar estimation were done.Results: On comparison of clinical signs in different dengue subgroups it was observed that the mean value of pulse, blood pressure and respiratory rate were significantly more deranged in the DSS group as compared to the DF group. Platelet count was significantly lower in all the sub groups whereas PT/aPTT was more dearranged in the DSS and DHF group as compared to the DF group. Comparison between the mean values of liver function test in different dengue sub groups had been shown, elevated transaminases, hypoproteinaemia and hypoalbuminaemia, in higher frequency in dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) as compared to classical dengue fever (DF) (P values significant). SGOT was significantly higher than the SGPT levels and SGOT was much more elevated in the DSS sub group compared to the DFS and DF group.Conclusions: The liver enzymes serum aminotransferase levels were significantly raised in patients with dengue shock syndrome compared to other two groups. Serum aminotransferases directly correlate with severity of infection in all the sub groups. Patients with secondary dengue infection were more prone for developing bleeding manifestations and shock syndrome.